• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者的间质性肺异常和肺纤维化:一项短期随访病例系列研究。

Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series.

机构信息

Thomas Jefferson University Hospital, Department of Radiology, 132 S 10th St., Philadelphia, PA 19017, USA.

Thomas Jefferson University Hospital, Department of Radiology, 132 S 10th St., Philadelphia, PA 19017, USA.

出版信息

Clin Imaging. 2021 Sep;77:180-186. doi: 10.1016/j.clinimag.2021.03.030. Epub 2021 Mar 29.

DOI:10.1016/j.clinimag.2021.03.030
PMID:33836413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8005381/
Abstract

Fibrotic lung changes are well-known complications of SARS, MERS, and ARDS from other causes and are anticipated in recovered COVID patients. However, there is limited data so far showing a temporal relationship between lung changes on imaging in the acute phase and follow-up imaging after recovery from the infection. We present 12 patients who demonstrate the development of interstitial lung changes and pulmonary fibrosis in the same distribution and pattern as the acute phase findings, up to 6 months after the acute infection, demonstrating a direct relationship between these changes and COVID-19 pneumonia.

摘要

纤维化肺部改变是 SARS、MERS 和其他原因引起的 ARDS 的已知并发症,在康复的 COVID 患者中也可预期。然而,目前有限的数据显示,在感染恢复后的急性阶段和随访成像之间,肺部影像学改变之间存在时间关系。我们介绍了 12 例患者,他们在急性感染后长达 6 个月的时间内,在相同的分布和模式下出现了间质性肺改变和肺纤维化,这表明这些改变与 COVID-19 肺炎之间存在直接关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/ebce60f13e65/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/384c7c19e0f1/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/d9b3270e4c92/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/93d171f34c10/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/8d8ed39257d6/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/8856e590897c/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/ebce60f13e65/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/384c7c19e0f1/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/d9b3270e4c92/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/93d171f34c10/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/8d8ed39257d6/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/8856e590897c/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de6f/8005381/ebce60f13e65/gr6_lrg.jpg

相似文献

1
Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series.COVID-19 患者的间质性肺异常和肺纤维化:一项短期随访病例系列研究。
Clin Imaging. 2021 Sep;77:180-186. doi: 10.1016/j.clinimag.2021.03.030. Epub 2021 Mar 29.
2
Persistence of post-COVID lung parenchymal abnormalities during the three-month follow-up.新冠后肺实质异常在随访三个月期间持续存在。
Adv Respir Med. 2021;89(5):477-483. doi: 10.5603/ARM.a2021.0090. Epub 2021 Oct 6.
3
Sequelae of COVID-19 pneumonia: Is it correct to label everything as post-COVID lung fibrosis?新冠病毒肺炎后遗症:将所有情况都归为新冠后肺纤维化,这样做对吗?
J Postgrad Med. 2021 Oct-Dec;67(4):224-227. doi: 10.4103/jpgm.jpgm_550_21.
4
Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis.新冠病毒肺炎和病毒性肺炎住院后的肺实质异常:一项系统评价和荟萃分析。
Thorax. 2023 Feb;78(2):191-201. doi: 10.1136/thoraxjnl-2021-218275. Epub 2022 Mar 25.
5
Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19.严重 COVID-19 后 1 年 CT 随访时的纤维化间质肺异常。
Radiology. 2021 Dec;301(3):E438-E440. doi: 10.1148/radiol.2021210972. Epub 2021 Jul 27.
6
Utility of the Enhanced Liver Fibrosis score as a blood biomarker of pulmonary fibrosis secondary to SARS-CoV-2 pneumonia.增强型肝纤维化评分作为 SARS-CoV-2 肺炎继发肺纤维化的血液生物标志物的效用。
Respir Med. 2023 Nov;218:107394. doi: 10.1016/j.rmed.2023.107394. Epub 2023 Aug 24.
7
Similarities and Differences of Early Pulmonary CT Features of Pneumonia Caused by SARS-CoV-2, SARS-CoV and MERS-CoV: Comparison Based on a Systemic Review.新型冠状病毒、严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒所致肺炎早期肺部CT特征的异同:基于系统评价的比较
Chin Med Sci J. 2020 Sep 30;35(3):254-261. doi: 10.24920/003727.
8
[Postinflammatroy pulmonary fibrosis of COVID-19: the current status and perspective].[新型冠状病毒肺炎炎症后肺纤维化:现状与展望]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Sep 12;43(9):728-732. doi: 10.3760/cma.j.cn112147-20200317-00359.
9
Follow-Up Analysis of Pulmonary Function, Exercise Capacity, Radiological Changes, and Quality of Life Two Months after Recovery from SARS-CoV-2 Pneumonia.新型冠状病毒肺炎康复两个月后肺功能、运动能力、影像学变化及生活质量的随访分析
Medicina (Kaunas). 2021 Jun 3;57(6):568. doi: 10.3390/medicina57060568.
10
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors.重新利用组蛋白去乙酰化酶抑制剂:一种有前途的策略,可用于对抗 COVID-19 幸存者中 TGF-β 信号促进的肺纤维化。
Life Sci. 2021 Feb 1;266:118883. doi: 10.1016/j.lfs.2020.118883. Epub 2020 Dec 11.

引用本文的文献

1
Pulmonary fibrosis followed by severe pneumonia in patients with COVID-19 infection requiring mechanical ventilation: a prospective multicentre study.COVID-19 感染患者机械通气后出现肺纤维化伴严重肺炎:一项前瞻性多中心研究。
BMJ Open Respir Res. 2024 Oct 4;11(1):e002538. doi: 10.1136/bmjresp-2024-002538.
2
Clinico-radiological and pulmonary function assessment of post-COVID-19 patients with respiratory symptoms.有呼吸道症状的新冠后患者的临床影像学和肺功能评估
J Family Med Prim Care. 2024 Aug;13(8):2912-2920. doi: 10.4103/jfmpc.jfmpc_1721_23. Epub 2024 Jul 26.
3
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.

本文引用的文献

1
Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: Preliminary experience.COVID-19 肺炎治愈后危重症患者的肺纤维化:初步经验。
Am J Emerg Med. 2020 Oct;38(10):2134-2138. doi: 10.1016/j.ajem.2020.05.120. Epub 2020 Jul 19.
2
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies.新冠康复者的肺纤维化:预测因素及风险降低策略
Pulm Med. 2020 Aug 10;2020:6175964. doi: 10.1155/2020/6175964. eCollection 2020.
3
Lung fibrosis: an undervalued finding in COVID-19 pathological series.
吡非尼酮和尼达尼布治疗肺纤维化:利弊分析
Pharmaceuticals (Basel). 2024 May 30;17(6):709. doi: 10.3390/ph17060709.
4
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study.新冠住院 3 年后的长期放射学和肺功能异常:一项纵向队列研究。
Eur Respir J. 2024 Jul 18;64(1). doi: 10.1183/13993003.01612-2023. Print 2024 Jul.
5
Lung Ultrasound Elastography by SWE2D and "Fibrosis-like" Computed Tomography Signs after COVID-19 Pneumonia: A Follow-Up Study.COVID-19肺炎后基于二维剪切波弹性成像的肺部超声弹性成像及“纤维化样”计算机断层扫描征象:一项随访研究
J Clin Med. 2023 Dec 5;12(24):7515. doi: 10.3390/jcm12247515.
6
Post-COVID-19 pulmonary fibrosis: An ongoing concern.新冠病毒感染后肺纤维化:持续受到关注。
Ann Thorac Med. 2023 Oct-Dec;18(4):173-181. doi: 10.4103/atm.atm_7_23. Epub 2023 Oct 17.
7
Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?肺纤维化:严重新型冠状病毒肺炎的短期还是长期后遗症?
Chin Med J Pulm Crit Care Med. 2023 Jun;1(2):77-83. doi: 10.1016/j.pccm.2022.12.002. Epub 2023 Jan 23.
8
Glucocorticoid pulse therapy in an elderly patient with post-COVID-19 organizing pneumonia: A case report.糖皮质激素脉冲疗法治疗老年新型冠状病毒肺炎后机化性肺炎1例报告
World J Clin Cases. 2023 Jun 16;11(17):4152-4158. doi: 10.12998/wjcc.v11.i17.4152.
9
Chronic Pulmonary Manifestations of COVID-19 Infection: Imaging Evaluation.COVID-19 感染的慢性肺部表现:影像学评估。
Radiology. 2023 Apr;307(2):e222379. doi: 10.1148/radiol.222379. Epub 2023 Jan 24.
10
Two in one: Overlapping CT findings of COVID-19 and underlying lung diseases.两病重叠:COVID-19 与基础肺部疾病的 CT 表现重叠。
Clin Imaging. 2023 Jan;93:60-69. doi: 10.1016/j.clinimag.2022.11.005. Epub 2022 Nov 12.
肺纤维化:COVID-19病理系列中一项被低估的发现。
Lancet Infect Dis. 2021 Apr;21(4):e72. doi: 10.1016/S1473-3099(20)30582-X. Epub 2020 Jul 28.
4
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.偶然在 CT 上发现的肺间质异常:弗勒施纳学会的立场文件。
Lancet Respir Med. 2020 Jul;8(7):726-737. doi: 10.1016/S2213-2600(20)30168-5.
5
Temporal radiographic changes in COVID-19 patients: relationship to disease severity and viral clearance.COVID-19 患者的时间分辨放射学变化:与疾病严重程度和病毒清除的关系。
Sci Rep. 2020 Jun 24;10(1):10263. doi: 10.1038/s41598-020-66895-w.
6
The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study.出院的 COVID-19 患者的肺部后遗症:一项短期观察性研究。
Respir Res. 2020 May 24;21(1):125. doi: 10.1186/s12931-020-01385-1.
7
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.肺纤维化与 COVID-19:抗纤维化治疗的潜在作用。
Lancet Respir Med. 2020 Aug;8(8):807-815. doi: 10.1016/S2213-2600(20)30225-3. Epub 2020 May 15.
8
Pulmonary fibrosis secondary to COVID-19: a call to arms?新型冠状病毒肺炎继发的肺纤维化:吹响战斗的号角?
Lancet Respir Med. 2020 Aug;8(8):750-752. doi: 10.1016/S2213-2600(20)30222-8. Epub 2020 May 15.
9
Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia.利用 COVID-19 肺炎治疗后出院患者的系列薄层 CT 和临床特征预测肺纤维化的发展。
Korean J Radiol. 2020 Jun;21(6):746-755. doi: 10.3348/kjr.2020.0215.
10
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.COVID-19 患者出院时的肺功能异常。
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.01217-2020. Print 2020 Jun.